Abstract

BackgroundCaveolae are plasma membrane subdomains of many mammalian cells that play critical roles in cellular processes, including endocytosis, signal transduction and tumorigenesis. Cavin proteins are essential for caveola formation, structure and function and are reported to be involved in various human diseases, but little is known about their expression and prognostic value in leukemia.MethodsWe performed a detailed analysis of Cavin family mRNA expression levels in different cancer tissues vs. normal tissues via the ONCOMINE, Gene Expression Profiling Interactive Analysis (GEPIA) and Cancer Cell Line Encyclopedia (CCLE) databases. Then, we used qRT-PCR and Western blotting to validate Cavin1-4 expression in 10 fresh leukemia samples. Moreover, we estimated their prognostic value in leukemia with the R programming language and GEPIA database.ResultsThe expression of Cavin members is low in most human cancers, especially in leukemia. Cavin-1 and Cavin-2 are often more expressed in myeloid leukemia than lymphoblastic leukemia, but Cavin-4 has the opposite pattern. Interestingly, low expression of CAVIN1 and CAVIN4 is correlated with poorer outcome but low CAVIN2 expression is associated with a significantly better leukemia prognosis in leukemia.ConclusionThe Cavin family showed significant expression differences between leukemia and normal cells. High Cavin-2 and low Cavin-4 levels predict poor survival and could be promising subtype diagnosis and prognosis biomarkers for leukemia.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.